Endometriosis Drug Forecasts and R&D 2016-2026

Feb 16, 2016, 09:00 ET from Visiongain

LONDON, February 16, 2016 /PRNewswire/ --

Revenues of that Expanding Market for Treating a Prevalent Women's Reproductive System Disorder

Endometriosis Medicines - Your 2016 Guide to Sales Potentials of that Rising, Underserved Female Health Market
What does the future hold for treating endometriosis, a common disease? Our new analysis forecasts sales of drugs treating that menstrual cycle disorder. Visiongain's report gives predictions to 2026 at overall world market, product and national level.

Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and increasing revenues endometrial therapies face. There you also explore trends, results, R&D and events, assessing commercial prospects.

Read on, then, to explore endometriosis treatments, including hormonal therapy. See below what future revenue that expanding pharmaceuticals market could generate.

Forecasts and other analysis to benefit your research, assessments, plans and decisions
10% of women worldwide have endometriosis, giving high, rising demand for those medicines. New drugs appear and promising candidates reach clinical trials. Discover, from 2016, what revenues and other progress are possible in that expanding market.

Besides sales forecasting to 2026, our survey shows recent results, growth rates and market shares. There you find original analysis. You also assess research and development. The study gives 53 tables, 61 charts and a research interview.

Our report's purpose is to help your research, analyses and decisions on the endometriosis drugs industry and market. Our work also benefits your authority and reputation for commercial insight, helping you compete and succeed.

The following sections explain how our new investigation benefits your work.

Predictions of drug sales - what is possible for those gynaecological medicines?
How will endometriosis medicines perform from 2015 to 2026 at world level? Our study forecasts revenues of these five brands:
• Lupron
• Eligard
• Zoladex

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com


• Depo-Provera
• Visanne.

Our analysis shows how products can compete and succeed. There you investigate trends, exploring challenges, changes and opportunities. See what is possible.

Discover what the future holds for endometriosis drugs and their developers, producers and marketers.

Endometriosis R&D holds high potential - explore advances, assessing prospects
That therapeutic segment holds much promising research and development. The new gonadotropin-releasing hormone (GnRH) antagonist approach to treat endometriosis may take over from the present GnRH agonist drugs, our study notes.

There exists great scope for new and improved medicines, benefiting pharma companies, healthcare providers and patients. Explore, from 2016, what is possible, staying ahead in knowledge to benefit your work.

Our report also shows you geographical sales predictions.

National markets - what is possible for those gynaecological drug revenues?
Advances in biopharma expand the range and use of endometriosis-treating drugs. Our study shows you individual revenue forecasts to 2026 for 11 national markets:
• US
Japan
Germany, France, Italy, Spain, UK (EU5)
China, Brazil, India, Russia (BRIC).

That way you assess countries and regions with highest revenues and potential sales growth. See what is possible, from 2016, in developed and developing countries.

That market gains momentum from rising disease prevalence, new and improved drugs and other forces stimulating treatment demand in that under-served market.

Influences, events and changes affecting companies treating endometriosis
Explore issues affecting that market, including these forces:
• Incidence and prevalence of that disorder, an often overlooked condition
• Raising disease awareness and overcoming reimbursement challenges
• Improving diagnosis and treatment of endometriosis - new therapies controlling hormones responsible for the build-up of endometrial tissue
• Hormone therapy, pain relievers (e.g. NSAIDs), contraceptives, medical devices and surgical options.

And gain insight on these developments, among others:
• Prospects for leading and emerging national markets - what the future holds for treating those vast patient populations
• Oral drug delivery for endometriosis - new therapies and novel drug candidates extend therapeutic and commercial potentials of that market
• Industry collaborations and R&D activities that stimulate progress.

In our report you also gain SWOT and PEST analysis, assessing what drives and restrains that expanding female health market.

That way you discover what is possible for leading pharma companies and specialists. Why miss out? Instead explore what the future holds for treating endometriosis, seeing the gains possible.

Leading companies and overall 2020 market value - what revenues are possible?
Our work predicts the world market for those drugs will reach $1.92 billion in 2020. That market will expand from 2016 to 2026. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.
 
That way you assess what organisations hold most potential. Those companies include these organisations:
• AbbVie
• Pfizer
• Bayer HealthCare
• AstraZeneca
• Astellas
• Takeda.

Discover what the future holds for participants in that industry, exploring what they do, as well as their commercial potentials.

6 ways Endometriosis Drug Forecasts and R&D 2016-2026 helps your work
Our new investigation benefits your work in these six main ways, helping you stay ahead in knowledge and benefit your authority:
• Revenues for endometriosis drugs at overall world level to 2026 - assess scope for investments, developments, production and marketing
• Leading products' sales to 2026 - discover predicted revenues of 5 prominent drugs, seeing how those medicines can compete and succeed
• National market forecasting to 2026 for 11 leading countries - explore the best regions for treatment demand, sales and revenue expansion
• Research and development - see progress, trends and prospects in that gynaecological R&D, assessing opportunities and possibilities
• Leading companies, news and opinion - examine participants in that rising market, gaining insight to help you stay ahead and succeed
• Analysis of what stimulates and restrains that market - assess challenges and strengths, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else.

Predictions for that female reproductive disorder - benefit your reputation for insight
With our independent study you assess products, companies, progress and possibilities for that female reproductive medicine. There discover the best commercial opportunities, as well as ways to help patients. See what is possible.

Having our analysis means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try that study, staying ahead. Our investigation shows you data, trends, opportunities and forecasts for that large, expanding female healthcare market. So avoid missing out - please get our new report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100

Or click on https://www.visiongain.com/Report/1576/Endometriosis-Drug-Forecasts-and-R-D-2016-2026

Organisations Mentioned in the Report 

Abbott Laboratories

AbbVie    

Addex Therapeutics

AEterna Zenaris

Aljazeera Hospital

Amanouchi Pharmaceutical Co.

AP Avadis Biotechnologies

Astellas Pharma

AstraZeneca

Atrix Laboratories

Australian National University

Bayer HealthCare

Brigham and Women's Hospital

Centre for Endocrinology and Reproductive Medicine

Centre for Epidemiology and Health Research

Children's Hospital Boston

Dongkook Pharmaceutical Co.

ElexoPharm GmbH

Eli Lilly

EndoCeutics

Euroscreen

Evotec    

Florida Hospital

Food and Drug Administration (FDA)

Fujisawa Pharmaceutical Co.

GlaxoSmithKline

Highland Clinical Research

Inc. Forendo Pharma Oy

Indian Brand Equity Foundation

Instituto de Investigacion Sanitaria La Fe

Isifer AB

Jacksonville Centre for Clinical Research

Jiangsu Kanion Pharmaceutical Co.

Kissei Pharmaceutical

Lipicard Technologies Limited

Medigene AG

Meditrina Pharmaceuticals

National Health Service

National Institute for Clinical Excellence

National Institute of Health

Neurocrine Biosciences

Northwestern University

ObsEva

Orphagen Pharmaceuticals

Pfizer

Philogen

PregLem SA

Repros Therapeutics

Research OutSmarts Endometriosis

Roche

Sanofi

Schering AG

SK Chemicals Co.

Takeda Pharmaceutical

Tolmar Therapeutics

Turku University Hospital

University Hospital (Angers)

University Hospital (Mo)

University Hospital (Rouen)

University of Arhus

University of Athens

University of Cagliari

University of Illinois

University of North Carolina

University of Oxford

ValiRX

Women's Health Care at Frost Street

 

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

SOURCE Visiongain